Does the media refer more to KURA or BEAM?

In the previous week, Kura Oncology and Kura Oncology both had 5 articles in the media. Beam Therapeutics' average media sentiment score of 1.30 beat Kura Oncology's score of 0.53 indicating that Beam Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kura Oncology 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Beam Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer KURA or RCUS?

In the previous week, Arcus Biosciences had 5 more articles in the media than Kura Oncology. MarketBeat recorded 10 mentions for Arcus Biosciences and 5 mentions for Kura Oncology. Arcus Biosciences' average media sentiment score of 0.75 beat Kura Oncology's score of 0.53 indicating that Arcus Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kura Oncology 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Arcus Biosciences 4 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend GMTX or KURA?

Kura Oncology has a consensus target price of $25.58, suggesting a potential upside of 182.69%. Given Kura Oncology's stronger consensus rating and higher probable upside, analysts plainly believe Kura Oncology is more favorable than Gemini Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gemini Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Kura Oncology 1 Sell rating(s) 2 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.69

Do analysts prefer KURA or MOR?

Kura Oncology presently has a consensus price target of $25.58, suggesting a potential upside of 182.69%. Given Kura Oncology's stronger consensus rating and higher probable upside, analysts plainly believe Kura Oncology is more favorable than MorphoSys. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kura Oncology 1 Sell rating(s) 2 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.69 MorphoSys 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher valuation & earnings, KURA or MOR?

MorphoSys has higher revenue and earnings than Kura Oncology. MorphoSys is trading at a lower price-to-earnings ratio than Kura Oncology, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Kura Oncology $67.48M 11.91 -$278.67M -$3.35 N/A MorphoSys $238.28M 11.99 -$205.35M -$3.48 N/A

Is KURA or MOR more profitable?

MorphoSys has a net margin of -226.79% compared to Kura Oncology's net margin of -411.19%. Kura Oncology's return on equity of -141.95% beat MorphoSys' return on equity. Company Net Margins Return on Equity Return on Assets Kura Oncology -411.19% -141.95% -43.28% MorphoSys -226.79% -694.31% -22.55%

Kura Oncology (KURA) Competitors

$9.05 0.00 (0.00%)

Closing price 06/12/2026 04:00 PM Eastern

Extended Trading

$9.06 +0.00 (+0.06%)

As of 06/12/2026 06:38 PM Eastern

Compare

KURA vs. DNLI, BEAM, RCUS, GMTX, and MOR

Should you buy Kura Oncology stock or one of its competitors? MarketBeat compares Kura Oncology with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Kura Oncology include Denali Therapeutics (DNLI), Beam Therapeutics (BEAM), Arcus Biosciences (RCUS), Gemini Therapeutics (GMTX), and MorphoSys (MOR). These companies are all part of the "pharmaceutical products" industry.

How does Kura Oncology compare to Denali Therapeutics?

Kura Oncology (NASDAQ:KURA) and Denali Therapeutics (NASDAQ:DNLI) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, analyst recommendations, dividends, valuation, institutional ownership, profitability and media sentiment.

Kura Oncology has higher earnings, but lower revenue than Denali Therapeutics. Denali Therapeutics is trading at a lower price-to-earnings ratio than Kura Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kura Oncology	$67.48M	11.91	-$278.67M	-$3.35	N/A
Denali Therapeutics	$330.53M	10.40	-$512.54M	-$2.88	N/A

92.9% of Denali Therapeutics shares are held by institutional investors. 7.6% of Kura Oncology shares are held by insiders. Comparatively, 12.5% of Denali Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Denali Therapeutics has a net margin of 0.00% compared to Kura Oncology's net margin of -411.19%. Denali Therapeutics' return on equity of -52.20% beat Kura Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kura Oncology	-411.19%	-141.95%	-43.28%
Denali Therapeutics	N/A	-52.20%	-43.86%

Kura Oncology has a beta of 0.36, suggesting that its stock price is 64% less volatile than the broader market. Comparatively, Denali Therapeutics has a beta of 1.03, suggesting that its stock price is 3% more volatile than the broader market.

In the previous week, Kura Oncology had 4 more articles in the media than Denali Therapeutics. MarketBeat recorded 5 mentions for Kura Oncology and 1 mentions for Denali Therapeutics. Denali Therapeutics' average media sentiment score of 1.87 beat Kura Oncology's score of 0.53 indicating that Denali Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Kura Oncology	Positive
Denali Therapeutics	Very Positive

Kura Oncology currently has a consensus target price of $25.58, suggesting a potential upside of 182.69%. Denali Therapeutics has a consensus target price of $34.25, suggesting a potential upside of 58.13%. Given Kura Oncology's higher possible upside, equities analysts plainly believe Kura Oncology is more favorable than Denali Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kura Oncology	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69
Denali Therapeutics	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.87

Summary

Denali Therapeutics beats Kura Oncology on 11 of the 17 factors compared between the two stocks.

How does Kura Oncology compare to Beam Therapeutics?

Kura Oncology (NASDAQ:KURA) and Beam Therapeutics (NASDAQ:BEAM) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, valuation, profitability, risk, dividends, earnings and analyst recommendations.

Beam Therapeutics has higher revenue and earnings than Kura Oncology. Beam Therapeutics is trading at a lower price-to-earnings ratio than Kura Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kura Oncology	$67.48M	11.91	-$278.67M	-$3.35	N/A
Beam Therapeutics	$139.74M	21.37	-$79.99M	-$0.68	N/A

Kura Oncology presently has a consensus target price of $25.58, indicating a potential upside of 182.69%. Beam Therapeutics has a consensus target price of $46.83, indicating a potential upside of 61.33%. Given Kura Oncology's higher probable upside, analysts clearly believe Kura Oncology is more favorable than Beam Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kura Oncology	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69
Beam Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.71

Beam Therapeutics has a net margin of -39.66% compared to Kura Oncology's net margin of -411.19%. Beam Therapeutics' return on equity of -29.00% beat Kura Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kura Oncology	-411.19%	-141.95%	-43.28%
Beam Therapeutics	-39.66%	-29.00%	-22.61%

In the previous week, Kura Oncology and Kura Oncology both had 5 articles in the media. Beam Therapeutics' average media sentiment score of 1.30 beat Kura Oncology's score of 0.53 indicating that Beam Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kura Oncology	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Beam Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

99.7% of Beam Therapeutics shares are owned by institutional investors. 7.6% of Kura Oncology shares are owned by insiders. Comparatively, 3.8% of Beam Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Kura Oncology has a beta of 0.36, suggesting that its share price is 64% less volatile than the broader market. Comparatively, Beam Therapeutics has a beta of 2.25, suggesting that its share price is 125% more volatile than the broader market.

Summary

Beam Therapeutics beats Kura Oncology on 12 of the 16 factors compared between the two stocks.

How does Kura Oncology compare to Arcus Biosciences?

Kura Oncology (NASDAQ:KURA) and Arcus Biosciences (NYSE:RCUS) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, profitability, dividends, risk and media sentiment.

Arcus Biosciences has a net margin of -156.36% compared to Kura Oncology's net margin of -411.19%. Arcus Biosciences' return on equity of -68.97% beat Kura Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kura Oncology	-411.19%	-141.95%	-43.28%
Arcus Biosciences	-156.36%	-68.97%	-35.27%

Kura Oncology has a beta of 0.36, suggesting that its share price is 64% less volatile than the broader market. Comparatively, Arcus Biosciences has a beta of 0.85, suggesting that its share price is 15% less volatile than the broader market.

92.9% of Arcus Biosciences shares are held by institutional investors. 7.6% of Kura Oncology shares are held by company insiders. Comparatively, 9.6% of Arcus Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Kura Oncology currently has a consensus target price of $25.58, suggesting a potential upside of 182.69%. Arcus Biosciences has a consensus target price of $35.10, suggesting a potential upside of 47.17%. Given Kura Oncology's stronger consensus rating and higher possible upside, equities research analysts plainly believe Kura Oncology is more favorable than Arcus Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kura Oncology	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69
Arcus Biosciences	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.58

Kura Oncology has higher earnings, but lower revenue than Arcus Biosciences. Arcus Biosciences is trading at a lower price-to-earnings ratio than Kura Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kura Oncology	$67.48M	11.91	-$278.67M	-$3.35	N/A
Arcus Biosciences	$247M	12.14	-$353M	-$3.18	N/A

In the previous week, Arcus Biosciences had 5 more articles in the media than Kura Oncology. MarketBeat recorded 10 mentions for Arcus Biosciences and 5 mentions for Kura Oncology. Arcus Biosciences' average media sentiment score of 0.75 beat Kura Oncology's score of 0.53 indicating that Arcus Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kura Oncology	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Arcus Biosciences	4 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Arcus Biosciences beats Kura Oncology on 11 of the 16 factors compared between the two stocks.

How does Kura Oncology compare to Gemini Therapeutics?

Gemini Therapeutics (NASDAQ:GMTX) and Kura Oncology (NASDAQ:KURA) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, media sentiment, dividends, institutional ownership, analyst recommendations, valuation, earnings and risk.

75.4% of Gemini Therapeutics shares are owned by institutional investors. 12.9% of Gemini Therapeutics shares are owned by company insiders. Comparatively, 7.6% of Kura Oncology shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Kura Oncology has a consensus target price of $25.58, suggesting a potential upside of 182.69%. Given Kura Oncology's stronger consensus rating and higher probable upside, analysts plainly believe Kura Oncology is more favorable than Gemini Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gemini Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Kura Oncology	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69

Gemini Therapeutics has higher earnings, but lower revenue than Kura Oncology. Gemini Therapeutics is trading at a lower price-to-earnings ratio than Kura Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gemini Therapeutics	N/A	N/A	-$71.87M	-$1.00	N/A
Kura Oncology	$67.48M	11.91	-$278.67M	-$3.35	N/A

In the previous week, Kura Oncology had 5 more articles in the media than Gemini Therapeutics. MarketBeat recorded 5 mentions for Kura Oncology and 0 mentions for Gemini Therapeutics. Kura Oncology's average media sentiment score of 0.53 beat Gemini Therapeutics' score of 0.00 indicating that Kura Oncology is being referred to more favorably in the news media.

Company	Overall Sentiment
Gemini Therapeutics	Neutral
Kura Oncology	Positive

Gemini Therapeutics has a net margin of 0.00% compared to Kura Oncology's net margin of -411.19%. Gemini Therapeutics' return on equity of -38.78% beat Kura Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gemini Therapeutics	N/A	-38.78%	-35.88%
Kura Oncology	-411.19%	-141.95%	-43.28%

Gemini Therapeutics has a beta of -0.12, indicating that its stock price is 112% less volatile than the broader market. Comparatively, Kura Oncology has a beta of 0.36, indicating that its stock price is 64% less volatile than the broader market.

Summary

Kura Oncology beats Gemini Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Kura Oncology compare to MorphoSys?

Kura Oncology (NASDAQ:KURA) and MorphoSys (NASDAQ:MOR) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their media sentiment, risk, analyst recommendations, valuation, institutional ownership, profitability, earnings and dividends.

18.4% of MorphoSys shares are held by institutional investors. 7.6% of Kura Oncology shares are held by insiders. Comparatively, 0.1% of MorphoSys shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Kura Oncology has a beta of 0.36, meaning that its share price is 64% less volatile than the broader market. Comparatively, MorphoSys has a beta of 1.2, meaning that its share price is 20% more volatile than the broader market.

In the previous week, Kura Oncology had 5 more articles in the media than MorphoSys. MarketBeat recorded 5 mentions for Kura Oncology and 0 mentions for MorphoSys. Kura Oncology's average media sentiment score of 0.53 beat MorphoSys' score of 0.00 indicating that Kura Oncology is being referred to more favorably in the media.

Company	Overall Sentiment
Kura Oncology	Positive
MorphoSys	Neutral

Kura Oncology presently has a consensus price target of $25.58, suggesting a potential upside of 182.69%. Given Kura Oncology's stronger consensus rating and higher probable upside, analysts plainly believe Kura Oncology is more favorable than MorphoSys.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kura Oncology	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69
MorphoSys	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

MorphoSys has higher revenue and earnings than Kura Oncology. MorphoSys is trading at a lower price-to-earnings ratio than Kura Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kura Oncology	$67.48M	11.91	-$278.67M	-$3.35	N/A
MorphoSys	$238.28M	11.99	-$205.35M	-$3.48	N/A

MorphoSys has a net margin of -226.79% compared to Kura Oncology's net margin of -411.19%. Kura Oncology's return on equity of -141.95% beat MorphoSys' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kura Oncology	-411.19%	-141.95%	-43.28%
MorphoSys	-226.79%	-694.31%	-22.55%

Summary

Kura Oncology beats MorphoSys on 9 of the 16 factors compared between the two stocks.

Get Kura Oncology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KURA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

KURA vs. The Competition

Export

Metric	Kura Oncology	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$803.37M	$3.40B	$6.74B	$12.07B
Dividend Yield	N/A	2.25%	2.67%	5.67%
P/E Ratio	-2.70	19.82	24.21	24.42
Price / Sales	11.91	305.69	512.04	109.94
Price / Cash	N/A	53.61	27.48	37.92
Price / Book	4.53	8.32	10.66	6.83
Net Income	-$278.67M	$23.94M	$3.57B	$337.67M
7 Day Performance	5.72%	1.84%	0.58%	1.17%
1 Month Performance	-1.84%	-0.04%	1.54%	3.16%
1 Year Performance	40.53%	44.82%	25.40%	30.58%

Kura Oncology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
KURA Kura Oncology	3.2131 of 5 stars	$9.05 flat	$25.58 +182.7%	+40.5%	$803.37M	$67.48M	N/A	130
DNLI Denali Therapeutics	3.2119 of 5 stars	$19.54 +0.1%	$34.25 +75.3%	+48.9%	$3.10B	$330.53M	N/A	430	Positive News
BEAM Beam Therapeutics	3.0781 of 5 stars	$29.78 +1.3%	$46.83 +57.3%	+70.2%	$3.02B	$139.74M	N/A	510	Positive News
RCUS Arcus Biosciences	2.9246 of 5 stars	$23.26 +0.3%	$35.10 +50.9%	+157.8%	$2.92B	$247M	N/A	500
GMTX Gemini Therapeutics	N/A	$67.00 -5.8%	N/A	+26.6%	$2.90B	N/A	N/A	30	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:KURA) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Kura Oncology (KURA) Competitors

KURA vs. DNLI, BEAM, RCUS, GMTX, and MOR

How does Kura Oncology compare to Denali Therapeutics?

Summary

How does Kura Oncology compare to Beam Therapeutics?

Summary

How does Kura Oncology compare to Arcus Biosciences?

Summary

How does Kura Oncology compare to Gemini Therapeutics?

Summary

How does Kura Oncology compare to MorphoSys?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KURA vs. The Competition

Kura Oncology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Kura Oncology (KURA) Competitors

KURA vs. DNLI, BEAM, RCUS, GMTX, and MOR

How does Kura Oncology compare to Denali Therapeutics?

Which has better earnings and valuation, KURA or DNLI?

Do institutionals and insiders hold more shares of KURA or DNLI?

Is KURA or DNLI more profitable?

Which has more volatility & risk, KURA or DNLI?

Does the media refer more to KURA or DNLI?

Do analysts prefer KURA or DNLI?

Summary

How does Kura Oncology compare to Beam Therapeutics?

Which has better earnings and valuation, KURA or BEAM?

Do analysts recommend KURA or BEAM?

Is KURA or BEAM more profitable?

Does the media refer more to KURA or BEAM?

Do insiders and institutionals believe in KURA or BEAM?

Which has more volatility and risk, KURA or BEAM?

Summary

How does Kura Oncology compare to Arcus Biosciences?

Is KURA or RCUS more profitable?

Which has more volatility and risk, KURA or RCUS?

Do insiders & institutionals hold more shares of KURA or RCUS?

Do analysts rate KURA or RCUS?

Which has stronger earnings & valuation, KURA or RCUS?

Does the media prefer KURA or RCUS?

Summary

How does Kura Oncology compare to Gemini Therapeutics?

Do institutionals & insiders hold more shares of GMTX or KURA?

Do analysts recommend GMTX or KURA?

Which has preferable valuation & earnings, GMTX or KURA?

Does the media favor GMTX or KURA?

Is GMTX or KURA more profitable?

Which has more risk & volatility, GMTX or KURA?

Summary

How does Kura Oncology compare to MorphoSys?

Do institutionals and insiders hold more shares of KURA or MOR?

Which has more risk and volatility, KURA or MOR?

Does the media prefer KURA or MOR?

Do analysts prefer KURA or MOR?

Which has higher valuation & earnings, KURA or MOR?

Is KURA or MOR more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KURA vs. The Competition

Kura Oncology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools